Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT01191320
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 102 participants
- Sponsor
- Repros Therapeutics Inc.
- Registry
-
NCT01191320
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01191320. Randomized; quadruple masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2014-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Secondary Hypogonadism
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Androxal
- Lead sponsor
- Repros Therapeutics Inc.
Record details
- Record id
cardio:ct-nct01191320- Content hash
c4768b626e16e7ccdc4294c7b5592bfcc8a490a6b43b838b78226102b1975769